Jump to main content

Publications

  1. Saggau, J., Kiefer, C., Bonasera, D., Schmidt, L., Grauvogel, L., Engel, P., Serrano Saenz, S., Thrussel, C., Rakhsh Khorshid, H., Kelepouras, K., Megyesfalvi, Z., Dome, B., Kruger, M., Montinaro, A., Abedpour, N., Rieser, E., Liccardi, G*., Walczak, H*. Combination of enhanced gene activation and cell death causes lethal inflammatory pulmonary fibrosis. BioRxiv 2026; preprint: 2026.09.03.749194. Under revision in Immunity/Cell. 
  2. Pang J., Al-Ani A.H., Patel K.M., Zhou Y., Young S.N., Chen J., Kong I., Barrios M., Rickard J.A., Chen S., Ma X., Shojaee F., Kim S.B., Foroughi S., Cawthorne W., Jacobsen A.V., Jois A., Weir A.L., Whitehead L.W., Rajasekhar P., Horne C.R., Lyu R., Mather L.J., Yip R.K.H., Tsui E., Azeez I., Tan T., Liang W., Sivanesan S., Metz A., Patwardhan A., Shea N., Iyngkaran G., Schneider D., Elford A.T., Beattie W., Macrae F., Liccardi G., Walczak H., Zhang Y., Sieber O.M., Spelman T., Giulino-Roth L., Christie M., Chen Y., Rogers K.L., Bowden R., Nicholson S.E., Lawlor K.E., Hawkins E.D., Christensen B., Samson A.L., Vince J.E., Murphy J.M. A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease. Science. 2026 Aug 27. doi: 10.1126/science.aeh7112.
  3. Tishina S., Dahlhaus A., Manik M., Mulalic L., Murr J., Kotliar M., Rakhsh-Khorshid H., Kostopoulou M., Hocher F., Stroh J., Beck J., Williams R.M., Balta G.G., Liu F., Abdallah A.T., Bebber C.M., Reese M., Lim J.K.M., Quaas A., Brägelmann J., Pasparakis M., Beleggia F., Balachandran S., Trauzold A., Liccardi G., Astsaturov I., Reichert M., Androulidaki A., von Karstedt S. Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis. Nature Communications 2026 Jun 15. doi: 10.1038/s41467-026-73189-8.
  4. Gabrielyan A., Simpson D. S., Bandala Sanchez E., Tenev T., Lechtenberg B. C., Saggau J., Bonasera D., Glatter T., Orme M., Kueh A., Herold M., Mariadason J. M., Iatropoulos G., Cheng Y., Wang J.-S., Walczak H., Liccardi G., Meier P., Silke J., and Feltham R., Anchr restricts TRAIL-dependent cholangitis-like injury by limiting liver cell death. SSRN. 2024; ID 4952464. Heliyon. 2026 Jul;12(12). doi: 10.1016/j.heliyon.2026.e45090.
  5. Kelepouras K., Saggau J., Bonasera D., Kiefer C., Locci F., Rakhsh-Khorshid H., Grauvogel L., Varanda A. B., Peifer M., Loricchio E., Montinaro A., Croon M., Trifunovic A., Prencipe G., Insalaco A., De Benedetti F., Walczak H., and Liccardi G.*+, STING induces ZBP1-mediated necroptosis independently of TNFR1 and FADD.Nature. 2025 Aug 20. doi: 10.1038/s41586-025-09536-4.
  6. Langpape A., Bonasera D., Stroh J., Reese M., Cartolano M., and Liccardi G.*+, and Silvia Von Karstedt*+, Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL). Cell Death and Discovery. 2025 Oct 31;11(1):495. doi: 10.1038/s41420-025-02826-w
  7. Hildebrandt X., Veli Ö., Hyoubi A., Zinngrebe J., Abdallah A. T., Rodefeld J., Hoffmann A., Gardeweg L., Kaya Ö., Wagner E., Lindhorst A., Poggenberg M., Wang Y., Dimmler J., Schillings J., Koci P., Bonechi F., Capuccino L. V., Kiefer C., Kelepouras K., Ghosh A., Noé F., Wolfrum C., Singer M., Liccardi G., Luedde T., Yavas A., Ghallab A., Hengstler J. G., Antczak P., Gericke M., Winkels H., Blüher M., Walczak H., Annibaldi A., Fischer-Posovszky P., and Peltzer N., Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome. Science Advances. 2025 Sep 19; 11(38): eadw2539. doi: 10.1126/sciadv.adw2539.
  8. Ros U., Martinez-Osorio V., Valiente P., Abdelwahab Y., Gojkovic M., Shalaby R., Zanna S., Saggau J., Wachsmuth W., Nemade H., … Kelepouras K., … Walczak H., Liccardi G., Mollenhauer M., Pasparakis M., Peltzer N., and Ana J. García-Sáez, MLKL activity requires a splicing-regulated, druggable intramolecular interaction.Molecular Cell. 2025 Apr 17; 85(8): 1589-1605.e12. doi: 10.1016/j.molcel.2025.03.015.
  9. Valdez Capuccino L., Kleitke T., Szokol B., Svajda L., Martin F., Bonechi F., Kreko M., Azami S., Montinaro A., Wang Y., Nikolov V., Kaiser L., Bonasera D., Saggau J., Scholz T., Schmitt A., Beleggia F., Reinhardt H. C., George J., Liccardi G., Walczak H., Tovari J., Bragelmann J., Montero J., Sos M. L., Orfi L., and Peltzer N., CDK9 inhibition as an effective therapy for small cell lung cancer. Cell Death and Disease. 2024; 15: 345. doi: 10.1038/s41419-024-05942-9.
  10. Kelepouras K., Saggau J., Varanda A. B., Zrilic M., Kiefer C., Rakhsh-Khorshid H., Lisewski I., Uranga-Murillo I., Arias M., Pardo J., Tonnus W., Linkermann A., Annibaldi A., Walczak H., and Liccardi G.*+, The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo. Cell Death and Differentiation. 2024 Jul; 31(7): 897–909. doi: 10.1038/s41418-024-01313-6
  11. Przyklenk M., Karmacharya S., Bonasera D., Pasanen-Zentz A. L., Kmoch S., Paulsson M., Wagener R., Liccardi G., and Schiavinato A., ANTXR1 deficiency promotes fibroblast senescence: implications for GAPO syndrome as a progeroid disorder. Scientific Reports. 2024 Apr 23; 14(1): 9321. doi: 10.1038/s41598-024-09321-y.
  12. Ibruli O., Rose F., Beleggia F., Schmitt A., Cartolano M., Fernandez L. T., Saggau J., Bonasera D., Kiljan M., Gozum G., Lichius L., Cai J., Niu L. N., Caiaffa M. I., Herter J. M., Walczak H., Liccardi G., Grüll H., Büttner R., Bosco G., George J., Thomas R. K., Bozek K., and Reinhardt H. C., A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade. Journal of Cancer Research and Clinical Oncology. 2024 Nov 14; 150(11): 496. doi: 10.1007/s00432-024-05942-9.
  13. Imai T., Lin J., Kaya G. G., Ju E., Kondylis V., Kelepouras K., Liccardi G., Kim C., and Pasparakis M., The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. Immunity. 2024 Jul 9; 57(7): 1497–1513.e6. doi: 10.1016/j.immuni.2024.04.016.
  14. Albert M. C., Uranga-Murillo I., Arias M., De Miguel D., Pena N., Montinaro A., Varanda A. B., Theobald S. J., Areso I., Saggau J., Koch M., Liccardi G., Peltzer N., Rybniker J., Hurtado-Guerrero R., Merino P., Monzon M., Badiola J. J., Reindl-Schwaighofer R., Sanz-Pamplona R., Cebollada-Solanas A., Megyesfalvi Z., Dome B., Secrier M., Hartmann B., Bergmann M., Pardo J., and Walczak H., Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality. Cell Death and Differentiation. 2024; 31(5): 544–557. doi: 10.1038/s41418-024-01278-6.
  15. Vitale I., Pietrocola F., … Liccardi G., … Kroemer G., Galluzzi L., and the NCCD 2023 Consortium, Apoptotic cell death in disease: current understanding of the NCCD 2023. Cell Death and Differentiation. 2023 May; 30(5): 1097–1154.
  16. Liccardi G.*+ and Annibaldi A.*+, MLKL post-translational modifications: road signs to infection, inflammation and unknown destinations. Cell Death and Differentiation. 2023 Feb; 30(2): 269–278. doi: 10.1038/s41418-022-01061-5
  17. Pernaute B., Pérez-Montero S., Sánchez Nieto J. M., Di Gregorio A., Lima A., Lawlor K., Bowling S., Liccardi G., Tomás A., Meier P., Sesaki H., Rutter G. A., Barbaric I., and Rodríguez T. A., DRP1 levels determine the apoptotic threshold during embryonic differentiation through a mitophagy-dependent mechanism. Developmental Cell. 2022; 57(11): 1316–1330. doi:10.1016/j.devcel.2022.04.012 
  18. Montinaro A., Areso Zubiaur I., Saggau J., Kretz A. L., Ferreira R. M. M., Hassan O., Kitzig E., Muller I., El-Bahrawy M. A., von Karstedt S., Kulms D., Liccardi G., Lemke J., and Walczak H., Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death and Differentiation. 2022 March 29; 28(3): 492–503. doi: 10.1038/s41418-020-00652-7.
  19. Garcia L. R., Tenev T., Newman R., Haich R. O., Liccardi G., John S. W., Annibaldi A., Yu L., Pardo M., Young S. N., Fitzgibbon C., Fernando W., Guppy N., Kim H., Liang L. Y., Lucet I. S., Kueh A., Roxanis I., Gazinska P., Sims M., Smyth T., Ward G., Bertin J., Beal A. M., Geddes B., Choudhary J. S., Murphy J. M., Aurelia Ball K., Upton J. W., and Meier P., Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance. Nature Communications. 2021; June 7 12(1): 3364. doi: 10.1038/s41467-021-23737-0.
  20. Smith H. G., Jamal K., Dayal J. H., Tenev T., Kyula-Currie J., Guppy N., Gazinska P., Roulstone V., Liccardi G., Davies E., Roxanis I., Melcher A. A., Hayes A. J., Inman G. J., Harrington K. J., and Meier P., RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Molecular Medicine. 2020; 12(6): e10979. doi: 10.15252/emmm.201910979.
  21. Ruiz E. J., Diefenbacher M. E., Nelson J. K., Sancho R., Pucci F., Chakraborty A., Moreno P., Annibaldi A., Liccardi G., Encheva V., Mitter R., Rosenfeldt M., Snijders A. P., Meier P., Calzado M. A., and Behrens A., LUBAC determines chemotherapy resistance in squamous cell lung cancer. Journal of Experimental Medicine. 2019; 216(2): 450–465. doi: 10.1084/jem.20180742.
  22. Anderton H., Bandala-Sanchez E., Simpson D. S., Rickard J. A., Ng A. P., Di Rago L., Hall C., Vince J. E., Silke J., Liccardi G.*+, and Feltham R.*+, RIPK1 prevents TRADD-driven, but TNFR1-independent, apoptosis during development. Cell Death and Differentiation. 2019; 26(5): 877–889. doi: 10.1038/s41418-018-0166-8.
  23. Liccardi G.*+, and Pentimalli F.*+, Cancer, immunity and inflammation. Report from the CDD Cambridge Conferences 2018 and 2019. Cell Death and Disease. 2019; 10(11): 798. doi: 10.1038/s41419-019-2031-5.
  24. Liccardi G., Ramos Garcia L., Tenev T., Annibaldi A., Legrand A. J., Robertson D., Feltham R., Anderton H., Darding M., Peltzer N., Dannappel M., Schunke H., Fava L. L., Haschka M. D., Glatter T., Nesvizhskii A., Schmidt A., Harris P. A., Bertin J., Gough P. J., Villunger A., Silke J., Pasparakis M., Bianchi K., and Meier P., RIPK1 and Caspase-8 ensure chromosome stability independently of their role in cell death and inflammation. Molecular Cell. 2019; 73(3): 413–428.e7. doi: 10.1016/j.molcel.2018.11.010.
  25. Simigdala N., Pancholi S., Ribas R., Folkerd E., Liccardi G., Nikitorowicz-Buniak J., Johnston S. R., Dowsett M., and Martin L. A., Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. British Journal of Cancer. 2018; 119(3): 313–322. doi: 10.1038/s41416-018-0175-5.
  26. Feltham R., Jamal K., Tenev T., Liccardi G., Jaco I., Domingues C. M., Morris O., John S. W., Annibaldi A., Widya M., Kearney C. J., Clancy D., Elliott P. R., Glatter T., Qiao Q., Thompson A. J., Nesvizhskii A., Schmidt A., Komander D., Wu H., Martin S., and Meier P., Mind Bomb regulates cell death during TNF signaling by suppressing RIPK1’s cytotoxic potential. Cell Reports. 2018; 23(2): 470–484. 10.1016/j.celrep.2018.03.054.
  27. Barry R., John S. W., Liccardi G., Tenev T., Jaco I., Chen C. H., Choi J., Kasperkiewicz P., Fernandes-Alnemri T., Alnemri E., Drag M., Chen Y., and Meier P., SUMO-mediated regulation of NLRP3 modulates inflammasome activity. Nature Communications. 2018; 9(1): 3001. doi: 10.1038/s41467-018-05457-6.
  28. Annibaldi A., Wicky John S., Vanden Berghe T., Swatek K. N., Ruan J., Liccardi G., Bianchi K., Elliott P. R., Choi S. M., Van Coillie S., Bertin J., Wu H., Komander D., Vandenabeele P., Silke J., and Meier P., Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. Molecular Cell. 2018; 69(4): 566–580.e5. doi: 10.1016/j.molcel.2018.01.027
  29. Liccardi G.*+, and Fava L. L.*+, Fiat Lux: illuminating the cell cycle. Cell Death Discovery. 2017; 3: 17042. doi: 10.1038/cddiscovery.2017.42.
  30. Jaco I., Annibaldi A., Lalaoui N., Wilson R., Tenev T., Laurien L., Kim C., Jamal K., Wicky John S., Liccardi G., Chau D., Murphy J. M., Brumatti G., Feltham R., Pasparakis M., Silke J., and Meier P., MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Molecular Cell. 2017; 66(5): 698–710.e5. doi: 10.1016/j.molcel.2017.05.003.
  31. Orme M. H., Liccardi G., Moderau N., Feltham R., Wicky John S., Tenev T., Aram L., Wilson R., Bianchi K., Morris O., Monteiro Domingues C., Robertson D., Tare M., Wepf A., Williams D., Bergmann A., Gstaiger M., Arama E., Ribeiro P. S., and Meier P., The unconventional myosin CRINKLED and its mammalian orthologue MYO7A regulate caspases in their signalling roles. Nature Communications. 2016; 7: 10972. doi: 10.1038/ncomms10972.
  32. Braso-Maristany F., Filosto S., Catchpole S., Marlow R., Quist J., Francesch-Domenech E., Plumb D. A., Zakka L., Gazinska P., Liccardi G., Meier P., Gris-Oliver A., Cheang M. C., Perdrix-Rosell A., Shafat M., Noel E., Patel N., McEachern K., Scaltriti M., Castel P., Noor F., Buus R., Mathew S., Watkins J., Serra V., Marra P., Grigoriadis A., and Tutt A. N., PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature Medicine. 2016; 22(11): 1303–1313. doi: 10.1038/nm.4198.
  33. Ribas R., Pancholi S., Guest S. K., Marangoni E., Gao Q., Thuleau A., Simigdala N., Polanska U. M., Campbell H., Rani A., Liccardi G., Johnston S., Davies B. R., Dowsett M., and Martin L. A., AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. Molecular Cancer Therapeutics. 2015; 14(9): 2035–2048. doi: 10.1158/1535-7163.MCT-15-0076.
  34. Liccardi G., Hartley J. A., and Hochhauser D., Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clinical Cancer Research. 2014; 20(13): 3496–3506. doi: 10.1158/1078-0432.CCR-13-2731.
  35. Liccardi G., Hartley J. A., and Hochhauser D., EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Research. 2011; 71(3): 1103–1114. doi: 10.1158/0008-5472.CAN-10-2384.

Patent

“Therapeutic Treatment.” Inventors: Bergmann M., De Miguel Samaniego D., Liccardi G., Pardo Jimeno J., Peltzer N., Secrier M., Taraborrelli L., and Walczak H. Priority date: 09 Oct 2020. Patent number: WO2021EP77942.

Dr. Gianmaria Liccardi

Dr. Gianmaria Liccardi

Principal Investigator (Junior Group Leader)